Guardion Health Sciences, Inc. (GHSI) financial statements (2021 and earlier)

Company profile

Business Address 15150 AVENUE OF SCIENCE, SUITE 200
SAN DIEGO, CA 92128
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments91012131162
Cash and cash equivalents91012131162
Receivables0000000
Inventory, net of allowances, customer advances and progress billings0111000
Inventory0111000
Prepaid expense0001000
Other current assets 001000
Other undisclosed current assets (0)(0)(1)(0)(0)(0)
Total current assets:91113141263
Noncurrent Assets
Operating lease, right-of-use asset0001111
Property, plant and equipment0000000
Intangible assets, net (including goodwill)0000022
Goodwill     22
Intangible assets, net (excluding goodwill)0000000
Deposits noncurrent assets0000000
Deferred costs      0
Other noncurrent assets0000000
Other undisclosed noncurrent assets(0)(0)(0)(0)(0)(0)(0)
Total noncurrent assets:1111133
TOTAL ASSETS:101214151396
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1101000
Accounts payable1100   
Accrued liabilities0000   
Other undisclosed accounts payable and accrued liabilities    000
Deferred revenue   0   
Debt    000
Deferred rent credit    000
Derivative instruments and hedges, liabilities0000000
Due to related parties000    
Other undisclosed current liabilities0000   
Total current liabilities:1111001
Noncurrent Liabilities
Long-term debt and lease obligation0000000
Operating lease, liability0000000
Other undisclosed noncurrent liabilities (0)(0)(0)   
Total noncurrent liabilities:0000000
Total liabilities:1112111
Stockholders' equity
Stockholders' equity attributable to parent91113141285
Common stock0000000
Additional paid in capital63616162574944
Accumulated deficit(54)(51)(49)(48)(46)(41)(39)
Total stockholders' equity:91113141285
TOTAL LIABILITIES AND EQUITY:101214151396

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues0010000
Amortization of lease incentives   (0)(0)  
Cost of revenue
(Cost of Goods and Services Sold)
(1)(0)(1)(0)(0)(0)(0)
Gross profit:(1)010000
Operating expenses(2)(2)(1)(2)(4)(3)(3)
Operating loss:(3)(2)(1)(2)(4)(2)(3)
Nonoperating income (expense)(0)0(0)0(0)(0)0
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Net loss:(3)(2)(1)(2)(4)(2)(3)
Other undisclosed net income (loss) attributable to parent000(0)00(0)
Net loss available to common stockholders, diluted:(3)(2)(1)(2)(4)(2)(3)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(3)(2)(1)(2)(4)(2)(3)
Comprehensive loss, net of tax, attributable to parent:(3)(2)(1)(2)(4)(2)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: